Poor Mobilization of Hematopoietic Stem Cells-Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 4, 2010, Pages 490-499

  Wuchter, Patrick ^a   Ran, Dan ^a,b   Bruckner, Thomas ^a   Schmitt, Thomas ^a   Witzens Harig, Mathias ^a   Neben, Kai ^a   Goldschmidt, Hartmut ^a   Ho, Anthony D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Poor mobilizer; Stem cell mobilization; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BODY WEIGHT; CANCER RADIOTHERAPY; CHILD; CONTROLLED STUDY; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; LEUKAPHERESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RISK FACTOR; SCHOOL CHILD; SEX; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT OUTCOME; AUTOTRANSPLANTATION; BLOOD; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77649335991     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.012     Document Type: Article

References (56)

1. Korbling M., Dorken B., Ho A.D., et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 67 (1986) 529-532
2. Reiffers J., Bernard P., David B., et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 14 (1986) 312-315
3. To L.B., Dyson P.G., Branford A.L., et al. Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous haemopoietic reconstitution in acute non-lymphoblastic leukaemia. Bone Marrow Transplant 2 (1987) 103-108
4. Bell A.J., Figes A., Oscier D.G., and Hamblin T.J. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients. Br J Haematol 66 (1987) 63-68
5. Kessinger A., Armitage J.O., Landmark J.D., Smith D.M., and Weisenburger D.D. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71 (1988) 723-727
6. Beyer J., Schwella N., Zingsem J., et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 13 (1995) 1328-1335
7. Schmitz N., Linch D.C., Dreger P., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347 (1996) 353-357
8. Hartmann O., Le Corroller A.G., Blaise D., et al. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 126 (1997) 600-607
9. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myélome. N Engl J Med 335 (1996) 91-97
10. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92 (1998) 3131-3136
11. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
12. Goldschmidt H., Hegenbart U., Wallmeier M., et al. Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy. Recent Results Cancer Res 144 (1998) 27-35
13. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
14. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21 (2003) 3918-3927
15. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25 (2007) 2554-2559
16. Villanueva M.L., and Vose J.M. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol 4 (2006) 521-530
17. Kornacker M., Stumm J., Pott C., et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 20 (2009) 722-728
18. Civin C.I., Strauss L.C., Brovall C., Fackler M.J., Schwartz J.F., and Shaper J.H. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 133 (1984) 157-165
19. Fruehauf S., Haas R., Conradt C., et al. Peripheral blood progenitor cells (PBPC) counts during steady-state hemopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 85 (1995) 2619-2626
20. Fruehauf S., Schmitt K., Veldwijk M.R., et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 105 (1999) 786-794
21. Weaver C.H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86 (1995) 3961-3969
22. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13 (1995) 2547-2555
23. To L.B., Haylock D.N., Simmons P.J., and Juttner C.A. The biology and clinical uses of blood stem cells. Blood 89 (1997) 2233-2258
24. Möhle R., Bautz F., Rafii S., Moore M.A., Brugger W., and Kanz L. The chemokine receptor CXCR-4 is expressed on CD34' hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell derived factor-1. Blood 91 (1998) 4523-4530
25. Lapidot T., and Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30 (2002) 973-981
26. Petit I., Szyper-Kravitz M., Nagler A., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3 (2002) 687-694
27. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201 (2005) 1307-1318
28. Cashen A.F., Nervi B., and DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 3 (2007) 19-27
29. Gianni A.M., Siena S., Bregni M., et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 2 (1989) 580
30. Haas R., Ho A.D., Bredthauer W., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18 (1990) 94
31. Elias A.D., Ayash L., Anderson K.C., et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte macrophage colony stimulating factor for hematologic support after high dose intensification for breast cancer. Blood 79 (1992) 3036
32. Bensinger W., Singer J., Appelbauf F., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Blood 81 (1993) 3158
33. Chao N.J., Schriber J.R., Grimes K., et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81 (1993) 2031
34. Ho A.D., Gluck S., Germond C., et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 7 (1993) 1738-1746
35. Haas R., Mohle R., Fruehauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83 (1994) 3787-3794
36. Sugrue M.W., Williams K., Pllock B.H., et al. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 39 (2000) 509-519
37. Tarella C., Di Nicola M., Caracciolo D., et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 30 (2002) 725-732
38. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 44 (2003) 815-820
39. Kuittinen T., Nousiainen T., Halonen P., et al. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 33 (2004) 907-912
40. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 37 (2006) 719-724
41. Akhtar S., Weshi A.E., Rahal M., et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 49 (2008) 769-778
42. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologus transplantation. Biol Blood Marrow Transplant 14 (2008) 1045-1056
43. Hosing C., Saliba R.M., Ahlawat S., et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recorrent or relapsed lymphoma. Am J Hematol 27 (2009) 335-337
44. Lane T.A., Law P., Maruyama M., et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85 (1995) 275-282
45. Corringham R.E.T., and Ho A.D. Rapid and sustained allogeneic transplantation using immunoselected CD34+-selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte-macrophage colony-stimulating factors. Blood 86 (1995) 2052
46. Goldschmidt H., Hegenbart U., Wallmeier M., et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 8 (1997) 243-246
47. Klaus J., Herrmann D., Breitkreutz I., et al. Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 78 (2007) 21-28
48. Abdallah A., Egerer G., Goldschmidt H., Wannenmacher M., Korbling M., and Ho A.D. Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol 112 (2001) 1012-1015
49. Abdallah A., Egerer G., Weber-Nordt R.M., Korbling M., Haas R., and Ho A.D. Long-term outcome in acute myelogenous leukemia autografted with mafosfamid-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia. Bone Marrow Transplant 30 (2002) 15-22
50. Devine S.M., Flomenberg N., Vesole D.H., et al. Rapid mobilization of CD34' cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 1095-1102
51. Flomenberg N., Devine S.M., DiPersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106 (2005) 1867-1874
52. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41 (2008) 331-338
53. Stiff P., Micallef I., McCarthy P., et al. Treatment with Plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells wehn given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant 15 (2009) 249-256
54. DiPersio J., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoetic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113 (2009) 5720-5726
55. Fruehauf S., Seeger T., Maier P., et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 34 (2006) 1052-1059
56. Fruehauf S., Veldwijk M.R., Seeger T., et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor AMD3100 (plerixafor) mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 31 (2009) 1-10